Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Never holds its gains so you are spot on!
Never holds its gains so you are spot on!
Concerned shareholder of Polished.com, Inc. urges investor collaboration
Jerald Hammann, a Polished.com shareholder, urges shareholders concerned about their investment in Polished.com to collaborate to increase the effectiveness of their actions.
Individual shareholders often lack the voting power to effect meaningful change at shareholder meetings. However, through collaboration, the opportunity exists for shareholders to discuss their investment objectives and assert a proactive posture in addressing board nominations and corporate governance proposals.
If you are interested in discussing your investment objectives relative to Polished.com or in discussing its 2024 annual shareholder meeting, please contact Jerald Hammann at investoradvocacy411 @rkhiii.
Disclaimers
This is not a solicitation of authority to vote your proxy. Please DO NOT send the author your proxy card. The author is not able to vote your proxy, nor does this communication contemplate such an event.
This is not an offer to enter into any agreement to act together with any shareholder for the purpose of acquiring, holding, voting, or disposing of equity securities. The author has no present intent to enter into a group pursuant to 17 CFR § 240.13d-5(b)(1).
The views expressed are those of the author as of the date referenced and are subject to change at any time based on market or other conditions. These views are not intended to be a forecast of future events or a guarantee of future results. These views may not be relied upon as investment advice. The information provided in this material should not be considered a recommendation to buy or sell any of the securities mentioned. It should not be assumed that investments in such securities have been or will be profitable. This communication should not be construed as a research report.
Sweet close $10.65. Hoping the pussies keep buying back at a loss. Ass Wipes
It's a rocket ship!!!!!! WOW
This is where we fight!
This is where we will fight
Back over $10.00, these cock suckers getting their shorts burned! Good! bastards
Thank you, good sir. I just read the news. I'm not impressed
Thank you, good sir. I just read the news. I'm not impressed
I saw that brother! Gotta make Coffee this is gonna be an interesting day
No telling how high she can go.
Could go insane! LOL
Direct Digital Holdings to Participate in the 2024 ICR Conference
HOUSTON, Dec. 18, 2023 /PRNewswire/ -- Direct Digital Holdings, Inc. (Nasdaq: DRCT) ("Direct Digital Holdings" or the "Company"), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC ("Colossus SSP"), Huddled Masses LLC ("Huddled Masses") and Orange142, LLC ("Orange142"), today announced that management will participate in the 2024 ICR Conference on January 8-10, 2024 at the Grande Lakes Resort in Orlando, FL.
Mark D. Walker, Chairman and Chief Executive Officer of Direct Digital Holdings, will participate in a fireside chat on Tuesday, January 9, 2024 at 8:00 AM ET. Management will also be available for meetings the same day.
For more information, or to schedule a meeting with management, please contact ICR.
NFOBIRD CO., LTD ANNOUNCES NEW BUSINESS COOPERATION IN INFORMATION TECHNOLOGY SYSTEM SOFTWARE DEVELOPMENT
HONG KONG, Dec. 18, 2023 /PRNewswire/ -- Infobird Co., Ltd (NASDAQ: IFBD) ("Infobird" or the "Company"), a software-as-a-service provider of AI-powered customer engagement solutions in China, today announced that a new business cooperation in software development of information technology system has been signed.
Recently, Infobird Technologies Limited (hereinafter referred to as "Infobird HK") and a company signed a new business contract, aiming to cooperate in software and IT system development, with a total value of US$1.8 million. The principal business of counterparty is Gig Economy Platform of localized life services. Henceforth, Infobird will intensify the investment in research and development of SaaS systems and software technologies and commit to explore more SaaS technologies applicable scenarios to help clients with business expansion.
Infobird will expand its business to the SaaS segmented scenarios, to penetrate the call centre SaaS business into specific scenes and seek better opportunities. Company has already identified new business models and obtained R&D achievements in several sectors, and prefers to focus on high margin market segmentation with more competitive advantage and positive cash flow generation.
About Infobird Co., Ltd
Infobird, headquartered in Hong Kong, is a software-as-a-service provider of innovative AI-powered, or artificial intelligence enabled, customer engagement solutions. For more information, visit Infobird's website at www.Infobird.com.
Forward-Looking Statements
Looking good in pre-markets doctor. I think $1.00 before the end of year:)))))
She has a low float. My feeling is it pops over $2.00
Over 80% of gastric cancers are attributed to H. pylori bacterial infection
Gastric cancer is the third most common cause of cancer related death in the world
H. pylori infection is also a major cause of peptic ulcers
IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic products, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Hp Detect™ Stool Antigen ELISA test (K232892), a new product that is designed to detect the presence of the H. pylori bacteria, which infects approximately 35% of the U.S. population. H. pylori infection is a disease which affects half the population of the world.
The Biomerica Hp Detect™ test detects the presence of the H. pylori bacteria which infects approximately 35% of the U.S. population. Over 80% of gastric cancers are attributed to H. pylori infection, and gastric cancer is the third most common cause of cancer-related death worldwide. Physicians and medical centers will be able use the results from the Hp Detect™ Stool Antigen test to diagnose the presence of H. pylori and assess H. pylori infection status after treatment.
Dr. William Chey, an expert in the management of H. pylori infection and Chief, Division of GI and Hepatology, Michigan Medicine, stated, “Testing for H. pylori eradication to assess status after treatment is crucial, especially in the context of increasing antibiotic resistance.”?
Biomerica’s Chief Executive Officer Zack Irani stated, “This FDA clearance is a milestone in our commitment to bringing a diagnostic solution for over 115 million people suffering from H. pylori infection across the U.S. We are particularly excited about this product as it has been shown to be highly accurate and has several key advantages for laboratories, physicians and patients. We have also created an efficient, low-cost manufacturing process that should enable high gross margins on this product.”
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration of use
ZORYVE foam provides rapid disease clearance and significant reduction in itch, one of the most burdensome symptoms of seborrheic dermatitis
First drug approved for seborrheic dermatitis with a new mechanism of action in over two decades
Seborrheic dermatitis affects more than 10 million people in the United States
Commercial product expected to be available by end of January
Management will host conference call on Monday, December 18 at 8:30 a.m. EST
WESTLAKE VILLAGE, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has approved the new drug application (NDA) for ZORYVE (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9 years of age and older. ZORYVE foam provides rapid disease clearance and significant reduction in itch, with nearly 80% of individuals achieving the primary efficacy endpoint of IGA Success and just over 50% of individuals reaching complete clearance at Week 8 in the STRATUM trial. ZORYVE is a once-daily steroid-free foam and the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.
“We know from dermatology clinicians and those living with seborrheic dermatitis that there has been a real struggle with disease clearance and treatment adherence due to lack of efficacy, difficulty treating certain body areas, inconvenient treatment regimens, and concerns about safety with long-term use,” said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis. “ZORYVE foam is a once-daily, steroid-free topical treatment that can be used anywhere on the body, including hair-bearing areas, with no limitation on duration of use. We are proud to deliver meaningful innovation through this approval of ZORYVE foam, and to offer a new topical treatment that effectively clears and controls the disease and can simplify its management for the millions of adults and adolescents living with seborrheic dermatitis.”
Seborrheic dermatitis affects more than 10 million people in the United States, and is a common, chronic, and recurrent inflammatory skin disease that causes red patches covered with large, greasy, flaking yellow-gray scales, and persistent itch. In individuals with darker skin tones, inflamed areas may not appear red, but instead can appear pink, slightly purple, or lighter in color than the surrounding skin. It occurs most often in areas of the body with oil-producing (sebaceous) glands, including the scalp, face (especially on the nose, eyebrows, ears, and eyelids), upper chest, and back. Hair-bearing areas make applying topicals like creams, gels, and ointments difficult.
“In the STRATUM trial, ZORYVE foam provided rapid disease clearance as early as Week 2 and significant itch relief in as little as 48 hours. In addition, almost 80% of patients achieved treatment success at Week 8. While multiple factors contribute to seborrheic dermatitis, inflammation and skin barrier dysfunction play key roles. ZORYVE has been shown to effectively reduce the signs of inflammation, redness, and scaling in patients with seborrheic dermatitis, and with its unique formulation, ZORYVE foam effectively delivers the drug without disrupting the skin barrier and has been shown to be safe and tolerable. ZORYVE foam is thus ideally formulated, having the potential to become the new standard of care for seborrheic dermatitis treatment,” said Andrew Blauvelt, MD, MBA, clinical investigator at Oregon Medical Research Center, and investigator on the STRATUM trial.
Beyond the appearance and irritation of physical symptoms, seborrheic dermatitis is associated with a decrease in quality of life and may negatively affect emotional well-being, self-esteem, and day-to-day life, including sleep and work. People with seborrheic dermatitis, and especially adolescents and school-age children, may suffer from social stigma, negative self-image, and low self-esteem associated with very visible skin diseases like seborrheic dermatitis.
“Approximately 10 million people in the United States have seborrheic dermatitis, but until today, there have been limited treatment options. We are thrilled with this FDA approval and are excited to bring to market a new, highly effective steroid-free topical formulation that can be used anywhere on the body,” said Frank Watanabe, president and CEO of Arcutis. “Our commercial team is ready and poised to launch ZORYVE foam very soon, and we are committed to ensuring affordable access to ZORYVE foam to those who may benefit from this novel treatment.”
Arcutis intends to make ZORYVE foam widely available via key wholesaler and dermatology pharmacy channels as a new treatment option by the end of January 2024. The Company is dedicated to responsible pricing and affordable access to therapy. The ZORYVE® Direct Program helps patients access their prescribed Arcutis medication. For patients with seborrheic dermatitis who have been prescribed ZORYVE, this patient support program helps patients navigate the payer process, assists patients with adherence, and includes the ZORYVE Direct Savings Card Program, which can help reduce out-of-pocket costs for eligible commercially insured patients.† Arcutis will also continue to offer the Arcutis CaresTM patient assistance program (PAP) that provides ZORYVE at no cost for financially eligible patients who are uninsured or underinsured.‡
Management will host a conference call on Monday, December 18 at 8:30 a.m. EST. A live webcast of the call and presentation material will be available on the “Events” section of the Company's Investor website. An archived version of the webcast will be available on the Arcutis website after the call.
ZORYVE Foam Clinical Data
The approval is supported by positive results from Arcutis’ Phase 2 and pivotal Phase 3 trials in seborrheic dermatitis. The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) and the Phase 2 (Trial 203) were parallel group, double-blind, vehicle-controlled studies evaluating the safety and efficacy of ZORYVE foam 0.3% in seborrheic dermatitis. Together the two studies enrolled 683 adults and adolescents ages 9 years and older.
The STRATUM study met its primary endpoint, with nearly 80% of ZORYVE foam treated individuals reaching Investigator Global Assessment (IGA) Success rate at Week 8 (79.5% ZORYVE foam vs 58.0% vehicle; P<0.0001). In Trial 203, 73% of individuals treated with ZORYVE foam achieved IGA Success (73.1% ZORYVE foam vs 40.8% vehicle; P<0.0001.) IGA Success was defined as an IGA score of “Clear” (0) or “Almost Clear” (1), plus a 2-grade IGA score improvement from baseline at Week 8.
Improvement with ZORYVE foam was seen early, with roflumilast demonstrating a statistically significant improvement compared to vehicle on IGA Success at Week 2, the first timepoint assessed in STRATUM. In addition, 50.6% of individuals in the ZORYVE foam treated arm reached complete clearance (IGA=0) at Week 8.
The STRATUM study also demonstrated statistically significant improvement over vehicle on all secondary endpoints, including itch, scaling, and erythema (redness). More than 60% of individuals achieved a ≥4-point reduction in itch at Week 8 as measured by Worst Itch-Numerical Rating Score (62.8% roflumilast foam vs 40.6% vehicle; P=0.0001), and significant improvements in itch were also reported at Week 2 and Week 4. Individuals treated with ZORYVE foam reported a 28% improvement in itch from baseline in 48 hours (compared to 13% on vehicle nominal P=0.0024).
In addition, more than 50% of individuals treated with ZORYVE foam achieved an erythema (redness) score of 0, and more than 50% achieved a scaling score of 0, at Week 8. Treatment with ZORYVE foam demonstrated a significantly larger improvement in patient reported outcomes as early as Week 2 as measured through Dermatology Life Quality Index (DLQI), with improvements maintained through Week 8.
ZORYVE foam was well-tolerated with a favorable safety and tolerability profile during up to 52 weeks of treatment. Incidence of Treatment Emergent Adverse Events (TEAEs) was low and similar between active treatment and vehicle, with most TEAEs assessed as mild to moderate severity. There were no treatment-related Serious Adverse Events (SAEs). Overall, the most common adverse reactions occurring in ≥1% of subjects in the combined Phase 2 and Phase 3 study populations were nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).
A Media Snippet accompanying this announcement is available by clicking on this link.
About ZORYVE®
ZORYVE (roflumilast) topical foam, 0.3%, is indicated for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older. Another formulation of ZORYVE, roflumilast cream 0.3%, is approved by the FDA for the topical treatment of plaque psoriasis in individuals 6 years of age and older. Both ZORYVE foam and cream are topical formulations of roflumilast, a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators. It is an established target in dermatology.
INDICATIONS
ZORYVE cream is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 6 years of age and older.
ZORYVE foam, 0.3%, is indicated for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.
IMPORTANT SAFETY INFORMATION
ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).
Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.
The most common adverse reactions (≥1%) for ZORYVE cream include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).
The most common adverse reactions (≥1%) for ZORYVE foam include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).
Please see full Prescribing Information for ZORYVE foam and full Prescribing Information for ZORYVE cream.
ZORYVE is for topical use only and not for ophthalmic, oral, or intervaginal use.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio that harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, seborrheic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, and X.
Forward-Looking Statements
NEWS
SunHydrogen Enters Consulting Agreement with 3 of Japan’s Most Esteemed Green Hydrogen Production Experts
CORALVILLE, IA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- SunHydrogen, Inc. (OTCQB: HYSR), the developer of a breakthrough technology to produce renewable hydrogen using sunlight and water, today announced that the Company has entered into a consulting agreement with three of Japan’s top experts in the field of photocatalytic green hydrogen production.
Beginning in December 2023, SunHydrogen is set to receive specialized guidance from Prof. Kazunari Domen, Dr. Hiroshi Nishiyama and Dr. Taro Yamada of the University of Tokyo on the design and optimization of SunHydrogen's panel technology, including the balance of systems, based on their experience. Their input will be crucial in enhancing process efficiency and reducing the overall levelized cost of hydrogen production for pilot scale demonstrations – Prof. Domen alone brings a highly decorated career of over 90,000 citations and over 800 publications.
Prof. Domen, Dr. Nishiyama and Dr. Yamada are all key participants in Japan’s ARPChem project, a collaborative research initiative backed by Japan’s New Energy and Industrial Technology Development Organization (NEDO) that demonstrated the feasibility of producing solar hydrogen through photocatalytic water splitting on an area scale of 100m² and a time scale of one year.
Moving forward, NEDO expects to spend 30 billion yen ($260 million) in support of ARPChem and the University of Tokyo as they work together to conduct a field test featuring photocatalytic green hydrogen panels.
"We are thrilled to embark on this collaboration with Prof. Domen, Dr. Nishiyama and Dr. Yamada, renowned leaders in photocatalytic green hydrogen production," said SunHydrogen’s Chief Scientific Officer Dr. Syed Mubeen. "Their vast experience and groundbreaking work in this field are invaluable assets for our team. We are looking forward to harnessing their insights on panel design and process scale-up to accelerate our pilot demonstrations."
About SunHydrogen, Inc. SunHydrogen is developing breakthrough technologies to make, store and use green hydrogen in a market that Goldman Sachs estimates to be worth $12 trillion by 2050. Our patented SunHydrogen Panel technology, currently in development, uses sunlight and any source of water to produce low-cost green hydrogen. Similar to solar panels that produce electricity, our SunHydrogen Panels will produce green hydrogen. Our vision is to become a major technology supplier in the new hydrogen economy. By developing, acquiring and partnering with other critical technologies, we intend to enable a future of emission-free vehicles, ships, data centers, aircrafts and more. To learn more about SunHydrogen, please visit our website at www.SunHydrogen.com.
Excellent bro! Thanks for the link!
You make great points! I feel 2024 will be their big growth year. Stock is dirt cheap under $1.00 IMHO
Thank you Drugdoctor, I appreciate your analysis. Also, read the news for a 2nd time today and it looks better than the first time I read it this morning. I feel many investors will read this over the weekend and maybe we can push the $1.00 next week :)
It breaks my heart to know that millions of children every year are born to starve to death. No explanation. Starving to death is the most painful way to die.
Brother,I have my very own spiritual saying "Age is a state of mind" Why do I say this? Because life is about learning. I am very young now and was very old when I was young. I don't have to explain because I know you understand. My children are much older than I am. And when I was young my parents gave me advice and I thought to myself "I'm not gonna listen to those jerks!" as the years passed I knew they were 100% correct. My kids are the very same way with me. I have tried so hard to make them understand, not only that I talk to many young people who want to confide in me. They don't listen to a word I say, they like my voice, it's soothing.
I feel this has been the case for 5,000 years. I can't make any take advise.
How did you know that I love that guy? Fantastic quote!!! Something just like that happened to me this morning.
It's so true! Most people don't learn from history. I have my theories and feel Albert Einstein would agree with me. My heart tells me that I'm 100% correct. I'm talking from biblical days to today!
It's so true! Most people don't learn from history. I have my theories and feel Albert Einstein would agree with me. My heart tells me that I'm 100% correct. I'm talking from biblical days to today!
Your words are facts! The problem is its difficult to find serious team members
Hey, thank you! Now I'm gonna see you a lot as I just gave you a member mark. You got a new follower! :))
Oh sweet! Nice I am very bullish! Nice to meet you B RY
Could you imagine if it's correct? BANG ZOOM to the MOON!
And the 3rd slime worm Law Firm joins the crowd to fleece the innocent.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Direct Digital Holdings, Inc. (DRCT)
NEW YORK, NY / ACCESSWIRE / December 15, 2023 / Levi & Korsinsky notifies investors that it has commenced an investigation of Direct Digital Holdings, Inc. ("DDH") (NYSE:DRCT) concerning possible violations of federal securities laws.
On December 11, 2023, White Diamond Research published a report entitled "A Mountain of Evidence Suggests That Much of Direct Digital Holdings Revenue May Be Fake and Is Hiding Its Uncollectible Accounts Receivable - 90%+ Downside". The report from White Diamond alleges that DDH "uses ‘accounts receivable insurance' to hide from investors what its true uncollectible accounts receivable is", which "puts the quality of the revenue in question"; notes that "[DDH] doesn't mention any patents and reports zero R&D expense for its technology", which "suggests that its tech isn't proprietary and isn't improving to keep up with the strong competition in the space"; and asserts that "[DDH] is practically broke, with a reported $5.5M in cash, accounts payable that almost doubled quarter over quarter to $45M, and a sizeable debt of $24M with a 15% interest rate." On this news, DDH's stock price fell 11.31%, to close at $10.90 per share on December 11, 2023. To obtain additional information, go to:
https://zlk.com/pslra-1/direct-digital-holdings-inc-lawsuit-submission-form?prid=60212&wire=1
or contact Joseph E. Levi, Esq. either via email at jlevi @Awiz3.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
I always liked your style, Zorro. BIG SMILES :))))))))))))
Something is telling me your $10.00 prediction is gonna be a reality in the not-too-distant future :)
Thank you, bro. I'm gonna hold the other half. I I feel confident
Thanks for that link. I will be using that site now. Very interesting :)
It is pauly! :)
NEWS
Genius Group Provides Updated Guidance, with Profitable 2023 on 43% to 60% Revenue Growth.
SINGAPORE, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, today updated financial guidance for the financial year ending December 31, 2023.
Genius Group had provided updated financial guidance during its H1 earnings call on Sep 29, 2023, which guidance is being updated further as follows, based on information through December 14, 2023:
Annual revenue is expected to be $27 million to $29 million compared to 2022 revenue of $18.2 million, a 43% to 60% increase.
Net profit is expected to be adjusted to $3.0 million to $5.0 million from prior guidance of an expected ($15.4) million to ($17.0) million net loss due to adjustments of certain contingent liabilities.
Student and user growth is expected to be between 5.7 million and 6.0 million, a 27% to 33% increase from 4.5 million students and users in 2022.
Roger Hamilton, CEO of Genius Group, commented: “In 2022, we had our IPO and completed six acquisitions. In 2023, we have not completed any acquisitions with all of our revenue coming from organic growth. If we meet our earnings guidance, we would achieve the financial goals we began the year with. While we have had many external factors to contend with while building our business, our growth is a testament to the strength of our global community, focus of our leadership team and innovations of our product and partnership teams with the launch of our Genie AI and Genius Metaversity.”
“We are optimistic about our growth prospects, together with the anticipated growth of the AI-driven Edtech industry as a whole, in 2024.”
About Genius Group
Genius Group is a leading entrepreneur Edtech and education group, with a mission to disrupt the current education model with a student-centered, life-long learning curriculum that prepares students with the leadership, entrepreneurial and life skills to succeed. Through its learning platform, GeniusU, the Genius Group has a member base of 5.4 million users in 200 countries, ranging from early age to 100.
For more information, please visit https://www.geniusgroup.net/
Notes to Guidance
All guidance set forth in this press release is guidance as to our anticipated results. Our results may differ from this guidance and will depend upon factors affecting performance for the balance of fiscal 2023. These numbers should not be relied upon, and our final numbers will be announced subsequent to our 2023 audit and will be reported in our Form 20-F for the fiscal year ending December 31, 2023, which will be filed with the SEC on or before April 30, 2024.
Investor Notice
Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described in our most recent Annual Report on Form 20-F, as amended for the fiscal year ended December 31, 2022, filed with the SEC on June 6, 2023 and August 3, 2023. If any of these risks were to occur, our business, financial condition or results of operations would likely suffer. In that event, the value of our securities could decline, and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See "Forward-Looking Statements" below.
Forward-Looking Statements
Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by the use of words such as “may,” “will,” “plan,” “should,” “expect,” “anticipate,” “estimate,” “continue,” or comparable terminology. Such forward-looking statements are inherently subject to certain risks, trends and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate and involve factors that may cause actual results to differ materially from those projected or suggested. Readers are cautioned not to place undue reliance on these forward-
Maybe. we shall see at 4 AM have a good night!